Butler A, Rigby M H, Scott J, Trites J, Hart R, Taylor S M
Dalhousie University, Halifax, Canada.
J Otolaryngol Head Neck Surg. 2016 May 27;45(1):34. doi: 10.1186/s40463-016-0147-1.
The purpose of this study was to evaluate the functional and oncological outcomes of patients treated for T3 laryngeal squamous cell carcinoma. Specifically comparing transoral laser microsurgery and radiotherapy/chemoradiotherapy treatment modalities.
A retrospective review of patients treated for T3 laryngeal SCC between 2002 and 2010 was undertaken.
Forty-nine patients were included. 15 cases were glottic, (9 treated with TLM, 6 with RT/CRT), 33 supraglottic (6 treated with TLM, 27 with RT/CRT) and 1 subglottic subsite (treated with RT/CRT). There was no statistical difference between treatment groups for 24 month locoregional control (72.3 %), overall survival (glottis 86.7 %, supraglottic 70.4 %) and disease specific survival (glottic 93.3 % and supraglottic 74.1 %). Overall laryngeal preservation (84.9 %) was also similar in both groups.
Our institution is expanding the application of TLM to selected patients with T3 laryngeal carcinoma. Oncological outcomes have not been jeopardized by this approach and the treatment is well tolerated by patients with few complications.
本研究旨在评估接受T3期喉鳞状细胞癌治疗患者的功能和肿瘤学结局。具体比较经口激光显微手术与放疗/放化疗的治疗方式。
对2002年至2010年间接受T3期喉鳞状细胞癌治疗的患者进行回顾性研究。
纳入49例患者。声门型15例（9例行经口激光显微手术，6例行放疗/放化疗），声门上型33例（6例行经口激光显微手术，27例行放疗/放化疗），声门下型1例（行放疗/放化疗）。治疗组间24个月局部区域控制率（72.3%）、总生存率（声门型86.7%，声门上型70.4%）和疾病特异性生存率（声门型93.3%，声门上型74.1%）无统计学差异。两组的总体喉保留率（84.9%）也相似。
我们机构正在扩大经口激光显微手术在选定的T3期喉癌患者中的应用。这种方法并未危及肿瘤学结局，且患者对该治疗耐受性良好，并发症较少。
Zotero 插件
